NCT05014646 2026-03-05
Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients
City of Hope Medical Center
Phase 2 Active not recruiting
Clinical Trials
6 trialsNCT04508790 2025-08-07
Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
City of Hope Medical Center
Phase 2 Recruiting
NCT06540937 2024-08-07
Phase II Clinical Study of Leflunomide in the Treatment of MEN-1 Neuroendocrine Tumor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT06229340 2024-01-29
NТО-RAS
N.N. Petrov National Medical Research Center of Oncology
Phase 2 Recruiting
NCT03952832 2019-11-14
Leflunomide in Treating Patients With High-Risk Smoldering Multiple Myeloma
City of Hope Medical Center
Phase 2 Withdrawn
NCT00003775 2012-09-13
Leflunomide in Treating Patients With Anaplastic Astrocytoma in First Relapse
Pfizer
Phase 2 Completed